ChiCTR2100045380: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYHA1813 Oral Solution in Patients with Recurrent or Advanced Solid Tumor |
|
|
| Recruiting | 1 | 77 | | SYHA1813 oral solution | Beijing Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University, Self-funded | Recurrent or advanced solid tumor | | | | |
NCT06157918: Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants |
|
|
| Not yet recruiting | 1 | 18 | NA | SYHA1813 oral solution (2.0g:25mg), SYHA1813 oral solution (20ml:200mg) | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Healthy Participants | 01/24 | 02/24 | | |
